Literature DB >> 22729444

Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension.

Christophe Baudouin1, Jean-Paul Renard, Jean-Philippe Nordmann, Philippe Denis, Yves Lachkar, Eric Sellem, Jean-François Rouland, Viviane Jeanbat, Stéphane Bouée.   

Abstract

Purpose. To determine the prevalence of ocular surface diseases and identify risk factors in a population of patients receiving antiglaucomatous eyedrops over the long term. Methods. An observational cross-sectional study was designed to investigate ocular surface signs and symptoms using simple clinical tools. An ocular surface disease intensity score was calculated based on 10 questions regarding ocular surface symptoms and signs with a 4-grade scale. Patients were classified into 3 groups (A, B, and C) according to this total score. A multinomial logistic regression was performed in order to identify risk factors for surface disease. Results. In an overall population of 516 patients, 49% belonged to group A, 30% to group B, and 21% to group C. The multivariate analysis showed that the following factors were correlated with the severity of ocular surface disease: patient age, number of daily eyedrops, past topical treatment changes for ocular intolerance (found in the history of 40% of the patients), intraocular pressure (found to be significantly higher in patients with more severe ocular surface disease), and glaucoma severity. Conclusions. Patients treated for primary open-angle glaucoma or ocular hypertension often have ocular surface diseases, more often and more severely in older patients receiving more drugs and presenting with more severe glaucoma. These high prevalence values might therefore have consequences on the burden of the disease in terms of adherence to treatment and quality of life.

Entities:  

Year:  2012        PMID: 22729444     DOI: 10.5301/ejo.5000181

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  36 in total

1.  Barriers to Glaucoma Medication Compliance Among Veterans: Dry Eye Symptoms and Anxiety Disorders.

Authors:  Jack Stringham; Noy Ashkenazy; Anat Galor; Sarah R Wellik
Journal:  Eye Contact Lens       Date:  2018-01       Impact factor: 2.018

Review 2.  Effects of Aging in Dry Eye.

Authors:  Cintia S de Paiva
Journal:  Int Ophthalmol Clin       Date:  2017

3.  Influence of Pilocarpine and Timolol on Human Meibomian Gland Epithelial Cells.

Authors:  Yi Zhang; Wendy R Kam; Yang Liu; Xiaomin Chen; David A Sullivan
Journal:  Cornea       Date:  2017-06       Impact factor: 2.651

4.  Dry eye specific quality of life in veterans using glaucoma drops.

Authors:  Andrew Camp; Sarah R Wellik; Jonathan H Tzu; William Feuer; Kristopher L Arheart; Ananth Sastry; Anat Galor
Journal:  Cont Lens Anterior Eye       Date:  2015-02-24       Impact factor: 3.077

5.  Analysis of the effects of preservative-free tafluprost on the tear proteome.

Authors:  Sebastian Funke; Sabine Beck; Katrin Lorenz; Marion Kotterer; Dominik Wolters; Natarajan Perumal; Norbert Pfeiffer; Franz H Grus
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

Review 6.  Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.

Authors:  Gábor Holló; Andreas Katsanos; Kostas G Boboridis; Murat Irkec; Anastasios G P Konstas
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

7.  Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity.

Authors:  S-Y Lee; T T Wong; J Chua; C Boo; Y F Soh; L Tong
Journal:  Eye (Lond)       Date:  2013-07-12       Impact factor: 3.775

8.  Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis.

Authors:  Paul Harasymowycz; Cindy Hutnik; Jean-François Rouland; Francisco J Muñoz Negrete; Mario A Economou; Philippe Denis; Christophe Baudouin
Journal:  Adv Ther       Date:  2021-04-23       Impact factor: 3.845

9.  A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients.

Authors:  Paolo Fogagnolo; Angelica Dipinto; Elisa Vanzulli; Emanuele Maggiolo; Stefano De Cilla'; Alessandro Autelitano; Luca Rossetti
Journal:  Adv Ther       Date:  2015-04-19       Impact factor: 3.845

10.  Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension.

Authors:  Ines Lanzl; Thomas Hamacher; Klaus Rosbach; Mohammed Osman Ramez; Robert Rothe; Eva Růžičková; Marta Karhanová; Friedemann Kimmich
Journal:  Clin Ophthalmol       Date:  2013-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.